Abstract
The aim of the present study was to develop and characterize rivastigmine loaded Human Serum Albumin (HSA) nanoparticles (NPs) for sustained release. Rivastigmine tartrate (RT) is a short acting cholinesterase inhibitor (ChEI) used for Alzheimer’s disease (AD). In the present study sustained release nanoparticulate formulation of RT was prepared, optimized (using 32 factorial design) and characterized (using biodegradable polymer HSA as a carrier). HSA NPs were prepared by desolvation-crosslinking technique using ethanol with variable drug/polymer ratios (1:1, 1:2, 1:3, and 1:5) and using glutaraldehyde as a crosslinking agent. All prepared nanoparticles were coated with polysorbate-80 to facilitate brain targeting via endocytosis. Effect of key formulation variables on particle size (PS) and percentage drug entrapment (PDE) of NPs was studied by using 32 factorial design. Among different ratios studied, 1:2 showed minimum PS of 83.71 ± 4.2 nm with highest PDE of 81.46 ± 0.76 %. FTIR interpretation showed that there is no interaction between the drug and excipients used, DSC thermograms indicated that RT was dispersed as an amorphous state in HSA NPs. SEM studies indicated that the drug was completely entrapped in HSA NPs. In vitro studies showed 55.59 ± 3.80% release of drug from HSA NPs in 12 h. The experimental results showed the suitability of HSA nanoparticles as a potential carrier for providing sustained delivery of RT.
Keywords: Desolvation-Crosslinking, Factorial design, Human Serum Albumin (HSA) nanoparticles, Rivastigmine Tartrate, Sustained release.
Current Drug Delivery
Title:Preparation and Characterization of Rivastigmine Loaded Human Serum Albumin (HSA) Nanoparticles
Volume: 11 Issue: 3
Author(s): Amelia M. Avachat, Yogesh M. Oswal, Kishor N. Gujar and Rohit D. Shah
Affiliation:
Keywords: Desolvation-Crosslinking, Factorial design, Human Serum Albumin (HSA) nanoparticles, Rivastigmine Tartrate, Sustained release.
Abstract: The aim of the present study was to develop and characterize rivastigmine loaded Human Serum Albumin (HSA) nanoparticles (NPs) for sustained release. Rivastigmine tartrate (RT) is a short acting cholinesterase inhibitor (ChEI) used for Alzheimer’s disease (AD). In the present study sustained release nanoparticulate formulation of RT was prepared, optimized (using 32 factorial design) and characterized (using biodegradable polymer HSA as a carrier). HSA NPs were prepared by desolvation-crosslinking technique using ethanol with variable drug/polymer ratios (1:1, 1:2, 1:3, and 1:5) and using glutaraldehyde as a crosslinking agent. All prepared nanoparticles were coated with polysorbate-80 to facilitate brain targeting via endocytosis. Effect of key formulation variables on particle size (PS) and percentage drug entrapment (PDE) of NPs was studied by using 32 factorial design. Among different ratios studied, 1:2 showed minimum PS of 83.71 ± 4.2 nm with highest PDE of 81.46 ± 0.76 %. FTIR interpretation showed that there is no interaction between the drug and excipients used, DSC thermograms indicated that RT was dispersed as an amorphous state in HSA NPs. SEM studies indicated that the drug was completely entrapped in HSA NPs. In vitro studies showed 55.59 ± 3.80% release of drug from HSA NPs in 12 h. The experimental results showed the suitability of HSA nanoparticles as a potential carrier for providing sustained delivery of RT.
Export Options
About this article
Cite this article as:
Avachat M. Amelia, Oswal M. Yogesh, Gujar N. Kishor and Shah D. Rohit, Preparation and Characterization of Rivastigmine Loaded Human Serum Albumin (HSA) Nanoparticles, Current Drug Delivery 2014; 11 (3) . https://dx.doi.org/10.2174/15672018113109990050
DOI https://dx.doi.org/10.2174/15672018113109990050 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Differences in Functional Brain Activation and Hippocampal Volume Among Amnestic Mild Cognitive Impairment Subtypes
Current Alzheimer Research Synthesis and Anticonvulsant Activity Evaluation of Some 1-alkoxy-4-(1H- 1,2,4-triazol-1-yl)phthalazines
Letters in Drug Design & Discovery Genome-Wide Expression Analysis of Valproate Action: A Systems Level Synthesis
Current Psychopharmacology Latest Advances Towards the Discovery of 5-HT7 Receptor Ligands
Mini-Reviews in Medicinal Chemistry Natural Medicine:The Genus Angelica
Current Medicinal Chemistry Coenzyme Q10 in Neurodegenerative Diseases
Current Medicinal Chemistry Approaching Neurological Diseases to Reduce Mobility Limitations in Older Persons
Current Pharmaceutical Design Immunology and Epilepsy: Clinical and Experimental Evidence
Current Immunology Reviews (Discontinued) Inhibitors of Glycine Transporter-1: Potential Therapeutics for the Treatment of CNS Disorders
Current Topics in Medicinal Chemistry Lifelong Endocrine Fluctuations and Related Cognitive Disorders
Current Pharmaceutical Design Cold-induced Anaphylaxis: The Case of a 9-year-old Child and Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Pleiotropic, Cardioprotective Effects of Omega-3 Polyunsaturated Fatty Acids
Mini-Reviews in Medicinal Chemistry Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer’s Disease: Results from a Double-Blind, Placebo-Controlled Trial
Current Alzheimer Research Phenylbutyric Acid Protects Against Spatial Memory Deficits in a Model of Repeated Electroconvulsive Therapy
Current Neurovascular Research Neurological Disorders of Purine and Pyrimidine Metabolism
Current Topics in Medicinal Chemistry Ion Channels as Medicinal Targets of Biological Toxins: The Impact of Automated Patch-Clamp Electrophysiology
Current Topics in Medicinal Chemistry Persistent Current Blockers of Voltage-Gated Sodium Channels: A Clinical Opportunity for Controlling Metastatic Disease
Recent Patents on Anti-Cancer Drug Discovery Subject Index to Volume 3
Current Drug Targets - CNS & Neurological Disorders Neonatal Brain Hemorrhage (NBH) of Prematurity: Translational Mechanisms of the Vascular-Neural Network
Current Medicinal Chemistry On Chemical Structures with Potent Antiepileptic/Anticonvulsant Profile
Mini-Reviews in Medicinal Chemistry